Gender-affirming care · UK
Feminising hormone therapy, done properly and monitored properly.
Oestrogen and an anti-androgen, prescribed and titrated by a GMC-registered gender specialist - with the informed-consent conversation, the fertility conversation, and the long-term monitoring that self-medication and NHS-waiting-list limbo cannot give you.
Indicative pricing
What private feminising hormone therapy costs in the UK.
Once stable, GP shared care can reduce ongoing costs considerably.
In short
A private initial consultation: £250–£450, seen within 4–12 weeks.
| Item | Indicative range | Typical duration | Frequency / turnaround |
|---|---|---|---|
| Initial gender specialist consultation | £250–£450 | 45–60 min | 1–4 weeks |
| Follow-up / titration review | £150–£300 | 20–30 min | 3-monthly year 1 |
| Baseline hormone and safety bloods | £150–£300 | Same day | 3–5 days |
| Follow-up bloods (each round) | £100–£200 | Same day | 3–5 days |
| Monthly medication (typical) | £30–£100 | n/a | Ongoing |
| GnRH analogue depot (per dose) | £150–£400 | 10 min IM | 4–12 weekly |
| Sperm banking (initial + first year) | £300–£800 | 1–3 visits | Before starting |
NHS care via a Gender Dysphoria Clinic remains free but waiting times are typically five to eight years in 2026. Private specialist fees vary by clinician; medication costs depend on route (patches cost more than tablets), and GnRH depots are the most expensive component.
The problem
The right specialist, the right route, the right monitoring.
Five-to-eight-year NHS waits, GPs uncertain about bridging prescriptions, and self-sourced regimens without bloods - feminising hormone therapy is failed by the system in three separate places.
-
Stuck on an NHS list?
A private assessment plus a supporting letter your GP can act on - safe monitored care while the NHS list moves.
-
Self-medicating and worried?
Come into monitored care without judgment. Route change, dose review, bloods - no lectures.
-
Want it done properly?
A GMC-registered gender specialist, WPATH SOC 8 framing, and titration to real targets - not a repeat-prescription conveyor belt.
When it helps
When private feminising hormone therapy is the right step.
The situations we see most, plus the one red flag on hormones that means an emergency rather than an appointment.
-
Long NHS GDC wait
Adult Gender Dysphoria Clinic waits in England are typically five to eight years in 2026. Private assessment is often four to twelve weeks.
-
Currently self-medicating
Bringing self-sourced regimens into safe, monitored care - bloods, dose review, and route change if oral is raising your VTE risk.
-
GP bridging prescription
A GMC 0-8-70 supporting note asking your GP to prescribe safely while you wait for NHS specialist care.
-
Switching from oral to transdermal
Age over 40, migraine, smoking or VTE risk - the patch is preferred and worth switching to.
-
Post-orchidectomy hormone care
HRT continues lifelong after gonadectomy - dose, monitoring and DEXA schedule need to be right.
-
Second opinion or dose review
A private review of your current regimen, blood targets and long-term monitoring plan.
-
Non-binary AMAB feminisation
Partial or low-dose feminisation is a legitimate goal - dosing is individualised, not a one-size regimen.
-
Red flag: calf swelling or chest pain
Sudden calf swelling, breathlessness or chest pain on hormones is a possible VTE or PE - same-day A&E, not a clinic booking.
Regimen options
Oral tablets are not the only route.
What each option on the table actually involves - and which fits which risk profile. Ethinyl oestradiol is avoided in modern practice because of its clot risk.
-
Oestradiol tablets (oral)
Oestradiol valerate or hemihydrate, typically 2–6 mg daily. Simple and cheap. Higher VTE risk than patches - avoided over 40 or with risk factors.
-
Oestradiol patches (transdermal)
Twice-weekly patches at 50–200 mcg. Preferred over age 40, in smokers, or with migraine or VTE risk. Steady levels, lower clot risk.
-
Oestradiol gel
1–4 mg daily applied to skin. Flexible dosing, no needles, avoids the liver first-pass - a good middle ground between tablets and patches.
-
Spironolactone (anti-androgen)
50–200 mg daily. Blocks testosterone and works well for most. Needs potassium and kidney checks; can cause frequent urination.
-
Cyproterone acetate
10–50 mg daily. Effective, but MHRA and EMA meningioma warnings mean it is now used cautiously and at the lowest effective dose.
-
GnRH analogue (goserelin, leuprorelin)
Depot injection every 4–12 weeks. Very effective testosterone suppression. Expensive, usually second-line after CPA concerns.
-
Micronised progesterone
100–200 mg daily, optional. Some report better breast development and mood; RCT evidence is limited but many specialists include it.
Safety and monitoring
What to expect on treatment - honestly.
Feminising hormone therapy is safe when properly monitored. The things worth planning are your route (oral vs patch), fertility, blood targets, and knowing the red flags.
-
VTE risk is real, and route matters
Oral oestrogen raises clot risk more than patches. Over 40, or with smoking, migraine or personal or family clot history, transdermal is strongly recommended.
-
Blood targets
Oestradiol 400–700 pmol/L, testosterone under 2 nmol/L. Higher oestradiol does not speed feminisation and does raise side-effect risk.
-
Fertility, before you start
Sperm production reduces within months and often does not return. Sperm banking is offered before starting - NHS-funded via referral, or £300–£800 privately for year one.
-
Timeline is slow and individual
Skin softens in 1–3 months. Breast development starts at 3–6 months and continues for 2–3 years, usually to 1–2 cup sizes. Facial hair reduces slowly and needs laser or electrolysis.
-
Voice does not change
Oestrogen does not raise voice pitch. Speech and language therapy is the right route - several NHS and private SLTs specialise in trans voice.
-
Prolactin and CPA
Cyproterone acetate raises prolactin and, at high dose, is linked to meningioma. Prolactin is checked annually; CPA is now used at the lowest effective dose.
-
Bone health after gonadectomy
Hormones must continue lifelong post-orchidectomy. DEXA every two years is reasonable if oestrogen is inadequate or you are post-gonadectomy.
-
Screening still applies
Cervical screening continues if you have a cervix. Chest wall screening is worth discussing once breast tissue develops. PSA interpretation is different post-orchidectomy.
-
Red flags
Sudden calf swelling, breathlessness, chest pain, severe headache, visual changes or unilateral weakness on hormones - same-day A&E.
Reading your clinic letter
Your specialist letter in four parts. Read the last one first.
Whichever regimen you are on, the letter the specialist sends you (and your GP) keeps to the same shape.
A quiet reminder
Endocrine language is precise and can read coldly - we translate it for you.
If you would like us to talk you through the letter before your next review, just ask.
- 01 Header
Diagnosis, goals and regimen chosen
The specialist records your history, goals (full feminisation, partial, non-binary), and the regimen - route, dose and anti-androgen - agreed with you.
- 02 Baseline
Baseline bloods and risk profile
Starting oestradiol, testosterone, LH/FSH, prolactin, LFTs, U&E, TFT, HbA1c and lipids - plus your VTE, cardiovascular and family-history risk.
- 03 Findings
Monitoring results and dose changes
Levels at each review, side effects, and any dose or route changes. Prolactin annually. DEXA if oestrogen is inadequate or you are post-gonadectomy.
- 04 Impression
Plan, red flags, and shared-care request
Read this first: your ongoing dose, next review date, red-flag symptoms to act on, and whether the letter asks your GP to take over prescribing.
Recognised by major UK insurers
Most UK private medical insurers exclude gender-affirming hormone therapy from standard cover, though some corporate schemes and enhanced plans include it.
Frequently asked
Everything we get asked about feminising hormone therapy.
Quick answers on NHS waits, GP bridging, cost, expected changes, fertility and long-term risks.
-
How long is the NHS wait for feminising hormones in 2026?
Adult Gender Dysphoria Clinic waits in England are typically five to eight years for a first appointment as of 2026, with variation between services (Sandyford in Glasgow and the Belfast Regional GIC also have long lists). Private assessment is usually four to twelve weeks.
-
Can my GP prescribe while I wait for NHS specialist care?
Sometimes. GMC 0-8-70 guidance supports GPs providing a bridging prescription while a patient is on an NHS gender-service waiting list, based on a supporting note from a gender specialist.
-
Tablets, patches or gel - which is best?
Patches are preferred if you are over 40, smoke, have migraine, or have any personal or family clot history - they carry lower VTE risk. Tablets are cheap and simple for lower-risk patients. Gel is a flexible middle ground. The specialist walks you through it before choosing.
-
How much does private feminising hormone therapy cost in the UK?
Roughly £250–£450 for the initial consultation, £150–£300 per follow-up, £100–£300 per set of bloods, and £30–£100 a month for medication. A GnRH analogue depot adds £150–£400 per dose. Once stable, GP shared care can reduce ongoing costs considerably.
-
What changes should I expect, and when?
Skin softens and body fat redistributes within the first 3–6 months. Breast development starts at 3–6 months and continues for 2–3 years, usually reaching 1–2 cup sizes. Muscle mass decreases, spontaneous erections reduce, and facial hair growth slows over 6–12 months - but facial hair usually needs laser or electrolysis for clearance. Voice does not change; speech and language therapy is the route for pitch and resonance.
-
Will I still be fertile?
Sperm production reduces within months of starting and often does not recover. If biological fatherhood matters to you at any point, sperm banking before starting hormones is the safe route - NHS-funded via referral to a fertility clinic, or £300–£800 privately for the first year of storage.
-
What are the main long-term risks?
Venous thromboembolism (highest with oral oestrogen and smoking, lowest with patches), stroke, gallstones, raised triglycerides, prolactinoma with high-dose cyproterone, and a small increased breast-cancer risk versus cis men - still lower than cis women. Bone density needs protecting if oestrogen is inadequate or after orchidectomy.
-
What happens after gonadectomy?
Hormone therapy is lifelong after orchidectomy - bones and cardiovascular health depend on it. The anti-androgen usually stops, oestrogen dose may adjust, and a DEXA scan every two years is a reasonable check.
-
When should I seek same-day medical help?
Sudden calf swelling or pain, breathlessness, chest pain, severe headache, visual changes, or unilateral weakness while on hormones need same-day A&E. These can be signs of clot, pulmonary embolism, stroke or, rarely, a pituitary problem.